Lipoprotein risk factors for cardiovascular disease in patients with type 2 diabetes mellitus treated with oral antihyperglycaemic agents

Aims:  To compare lipoprotein risk factors for cardiovascular disease (CVD) in patients with type 2 diabetes mellitus (DM) treated with a sulphonylurea (SU) compound only, metformin (MET) only, or combined SU + MET.

[1]  G. Reaven,et al.  Further Evidence for a Central Role of Adipose Tissue in the Antihyperglycemic Effect of Metformin , 1998, Diabetes Care.

[2]  A. Tenenbaum,et al.  Antihyperglycemic Treatment in Diabetics with Coronary Disease: Increased Metformin-Associated Mortality over a 5-Year Follow-Up , 1999, Cardiology.

[3]  R. Krauss,et al.  Identification of multiple subclasses of plasma low density lipoproteins in normal humans. , 1982, Journal of lipid research.

[4]  R. Marfella,et al.  Metformin Improves Glucose, Lipid Metabolism, and Reduces Blood Pressure in Hypertensive, Obese Women , 1993, Diabetes Care.

[5]  G. Reaven,et al.  Results of a Placebo-Controlled Study of the Metabolic Effects of the Addition of Metformin to Sulfonylurea-Treated Patients: Evidence for a central role of adipose tissue , 1997, Diabetes Care.

[6]  P. Fu,et al.  Enzymatic determination of total serum cholesterol. , 1974, Clinical chemistry.

[7]  G. Reaven,et al.  Effects of metformin on glucose, insulin and lipid metabolism in patients with mild hypertriglyceridaemia and non-insulin dependent diabetes by glucose tolerance test criteria. , 1991, Diabete & metabolisme.

[8]  Nicollerat Ja.  Implications of the United Kingdom Prospective Diabetes Study , 1998, Diabetes Care.

[9]  R. Holman,et al.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.

[10]  C. Sirtori,et al.  Long-term treatment with metformin in a large cohort of hyperlipidemic patients , 1978 .

[11]  P. Palumbo,et al.  Metformin: Effects on CardiovascularRisk Factors in Patients withNon–Insulin-Dependent Diabetes Mellitus , 1998 .

[12]  U. Smith,et al.  Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors , 1991, Journal of internal medicine.

[13]  Robert M. Anderson,et al.  Prevention or delay of type 2 diabetes. , 2004, Diabetes care.

[14]  G. Lindberg,et al.  Increased mortality in Type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational study , 2000, Diabetologia.

[15]  M Ai,et al.  Relationship between hyperinsulinemia and remnant lipoprotein concentrations in patients with impaired glucose tolerance. , 2000, The Journal of clinical endocrinology and metabolism.

[16]  K. Bjerve,et al.  Metformin improves blood lipid pattern in nondiabetic patients with coronary heart disease , 1996, Journal of internal medicine.

[17]  Robert M. Anderson,et al.  5. Prevention or Delay of Type 2 Diabetes , 2016, Diabetes Care.

[18]  J. Sternberg,et al.  A New and Rapid Method for the Determination of Glucose by Measurement of Rate of Oxygen Consumption , 1968 .

[19]  G. Reaven,et al.  Combined metformin-sulfonylurea treatment of patients with noninsulin-dependent diabetes in fair to poor glycemic control. , 1992, The Journal of clinical endocrinology and metabolism.

[20]  B. Sobel,et al.  A Review of Metabolic and Cardiovascular Effects of Oral Antidiabetic Agents: Beyond Glucose-Level Lowering , 1999, Journal of cardiovascular risk.

[21]  M. Uusitupa,et al.  Cholesterol lowering effect of metformin in combined hyperlipidemia: placebo controlled double blind trial. , 1990, Annals of medicine.

[22]  R. Havel,et al.  Evaluation of an immunoseparation method for quantitative measurement of remnant-like particle-cholesterol in serum and plasma. , 1998, Clinical chemistry.

[23]  G. Reaven.  Effect of metformin on various aspects of glucose, insulin and lipid metabolism in patients with non-insulin-dependent diabetes mellitus with varying degrees of hyperglycemia. , 1995, Diabetes/metabolism reviews.

[24]  P. Palumbo.  Metformin: effects on cardiovascular risk factors in patients with non-insulin-dependent diabetes mellitus. , 1998, Journal of diabetes and its complications.